4 Undervalued Biotechnology & Medical Research Stocks for Wednesday, April 26
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Wednesday, April 26 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3’-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Commentary & Analysis
7 Undervalued Biotechnology & Medical Research Stocks for Tuesday, February 21
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Tuesday, February 21 based on AAII’s Stock Grades.Cynthia McLaughlin
3 Undervalued Biotechnology & Medical Research Stocks for Monday, January 09
Discover the top 3 undervalued Biotechnology & Medical Research stocks for Monday, January 09 based on AAII’s Stock Grades.Jack Gilleland
Is NuCana PLC (NCNA) a Good Investment?
Learn more about NuCana PLC (ADR)’s (NCNA) stock grades for Growth, Momentum and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jenna Brashear
Financial Summary
| Share Statistics | NCNA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.7 | $269.5 | 4% |
|
| Shares Out (Mil) | 5.6 | 54.2 | 15% |
|
| Institutional Ownership | 99.8% | 93.0% | 94% |
|
| Float (Mil) | 4.3 | 42.1 | 11% |
|
| Beta | 2.22 | 0.95 | 94% |
|
| Avg Daily Volume (000s) | 27 | 609 | 23% |
|
| Price Change (52-week) |
(66.9%) | 54.5% | 11% |
|
| Growth | NCNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 1.2% | (10.1%) | 41% |
|
| EPS (5yr) | na | 15.4% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NCNA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($43) | 27% |
|
| EPS (TTM) | ($3.169) | ($1.500) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($31) | 23% |
|
| Net Cash Flow (TTM) (Mil) | $15 | $2 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | ($19) | $175 | 1% |
|
| Valuation | NCNA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.21 | 2.60 | 3% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NCNA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (45.7%) | (47.4%) | 12% |
|
| ROE | (69.7%) | (54.9%) | 12% |
|
| Liabilities to Assets | 21.4% | 29.3% | 14% |
|
| F-Score | 3 | 3 | 18% |
|
NuCana plc did not pass any screens on 9/21/2026.
